Cantitate/Preț
Produs

Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines

Autor Rebecca Sheets, Kathryn C. Zoon, Mark Schenerman, Susan Neadle, Christopher Hamlin, Ivana Knezevic, Mehmet Tosun
en Limba Engleză Paperback – iul 2025
Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines serves as an introduction to the international regulatory arena in which biologicals are developed and offers an overview of the processes and insight into the scientific concepts underpinning global regulations. In this new edition the book provides more in-depth coverage of Quality by Design, Combination Products, Quality Target Product Profiles, Risk Management Plans and REMS, and switching from reliance on in vivo to in vitro analytical methods. This new edition also reflects the new developments and processes accelerated by the COVID-19 vaccine experience, including emergency use authorizations and conditional marking authorizations. New pedagogic elements and case studies have been added to improve learning outcomes for students. This book provides multiple levels of readership with guidance on basic concepts, a detailed look at regulatory challenges, and practical insight into how regulators consider regulatory science and regulatory process issues across various regions with emphasis on the European Medicines Agency and the U.S. Food and Drug Administration. Graduate students will benefit from the new pedagogic features. Regulatory professionals will have in Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines a complete guide to navigate through the approval process.


  • New chapters on Advanced Therapy Medicinal Products (including cell and gene therapies), Combination Products, and Pharmacovigilance
  • Presents new and updated case studies, including lessons learned from the development of COVID Vaccines
  • More in-depth coverage on Quality by Design, Quality Target Product Profiles, and Pharmacovigilance
  • Chapters focusing on the principles in regulating Biosimilars, In Vitro Diagnostics, Advanced Therapy Medicinal Products, and Combination Products
  • Covers general biologicals development and authorization regulatory processes as well as scientific principles for CMC, preclinical and clinical development
  • Also covers ethical considerations for use of laboratory animals and human subjects protections, as well as genetically modified organisms used in or as medicines
Citește tot Restrânge

Preț: 70593 lei

Preț vechi: 74307 lei
-5% Nou

Puncte Express: 1059

Preț estimativ în valută:
13516 14075$ 11214£

Carte nepublicată încă

Doresc să fiu notificat când acest titlu va fi disponibil:

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780443219887
ISBN-10: 0443219885
Pagini: 450
Dimensiuni: 191 x 235 mm
Ediția:2
Editura: ELSEVIER SCIENCE

Cuprins

SECTION I REGULATORY PROCESS 1. Introduction to the Regulatory Process for Biologicals 2. International Regulatory Convergence 3. Quality by Design (QbD) Approach to Discovery and Development 4. Communications and Formal Meetings With Regulators: Focusing on the Process Before Clinical Trial 5. Clinical Trial Authorization and investigational New Drug Applications 6. Marketing Authorization 7. Alternative Regulatory Pathways and Special Programs 8. Variations or Changes to an Approved Application 9. Good "X" Practices 10. Audits and Regulatory Compliance inspections SECTION II REGULATORY SCIENCE PART I PRECLINICAL 11. Preclinical Safety and Toxicology 12. Preclinical Pharmacology , Proof-of-Principle 13. Institutional Biosafety Committees and Regulation of Genetically Modified Organisms 14. Risk Assessments PART II PRODUCT 15. Product Construction, Manufacture, and Process Validation 16. Analytical Method Development and Validation Leading to Control Strategy and Lot Release PART Ill CLINICAL 17. Regulatory Aspects of Clinical Trials 18. Pharmacovigilance and RiskMAPs 19. Clinical Trial Ethics, Human Subjects Protections, and the Informed Consent process 20. Independent Ethics Committees and Institutional Review Boards SECTION Ill PRODUCT-SPECIFIC REGULATORY PROCESSES 21. Biosimilars 22. In Vitro Diagnostics and Biotech Medical Devices 23. Combination Products 24. Regulatory Policy and Public Health Policy